SCHEMBL6289350

SCHEMBL6289350

O=C(O)c1cc2cc(Cc3ccc(F)c(F)c3)cnc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 2/20 0.45
KDM5B Q9UGL1 2/20 0.45
VNN1 O95497 1/20 0.39
ABL1 P00519 4/20 0.38
JAK2 O60674 1/20 0.38
ZAP70 P43403 1/20 0.38
SYK P43405 1/20 0.38
DAO P14920 1/20 0.38
SRC P12931 2/20 0.37
KDM4E B2RXH2 1/20 0.37
PDPK1 O15530 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
NFKB1 P19838 1/20 0.37
APEX1 P27695 1/20 0.37
CYP2C19 P33261 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6289393 0.73 KDM5A (0.40) KDM5AKDM5BVNN1JAK2ZAP70
SCHEMBL297192 0.73 KDM4E (0.51) ABL1DAOSRCKDM4EPDPK1
SCHEMBL6288797 0.72 MEN1 (0.46) KDM5AKDM5BVNN1JAK2ZAP70
SCHEMBL2106960 0.70 F7 (0.56) ABL1DAOSRCKDM4EPDPK1
SCHEMBL23147687 0.69 ULK1 (0.45) ABL1DAOSRCKDM4EPDPK1
SCHEMBL29721772 0.69 ULK1 (0.45) ABL1DAOSRCKDM4EPDPK1
SCHEMBL27248788 0.69 ABL1 (0.38) ABL1SRC
SCHEMBL31296111 0.69 SMAD3 (0.50) ABL1DAOSRCKDM4EPDPK1
SCHEMBL13625358 0.68 PIN1 (0.51) ABL1DAOSRCKDM4EHPGD
SCHEMBL15738800 0.68 DAO (0.45) ABL1JAK2DAOSRCKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949651-B2 Fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-09-27 US disclosed
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors LINCOLN FOODSERVICE PRODUCTS INC. 2004-02-19 US disclosed
WO-2004014375-A2 FUSED BICYCLIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 KDM5A 899/4885KDM5B 949/4885VNN1 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.